查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1574135

基因組學人工智慧 (AI) 市場：2024-2029 年預測

Artificial Intelligence (AI) in Genomics Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 140 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

基因組學領域的人工智慧 (AI) 市場預計將從 2024 年的 1,904,018,000 美元增加到 2029 年的 7,785,766,000 美元，預測期內複合年成長率為 32.53%。

隨著對精準醫療和針對特定健康疾病的標靶治療的需求不斷增加，基因組學領域的人工智慧市場正在快速成長。由於基因組學研究舉措的激增以及對更好的資料管理和整合解決方案的需求不斷成長，預計該市場將擴大。該市場應用於藥物發現、疾病診斷和治療規劃的各個領域，有助於發現新的藥物標靶並提高治療效果。

此外，可以透過分析用於疾病診斷的大型資料組資料集集來識別早發疾病訊號，並根據患者的病情量身定做治療計劃。人工智慧可以根據基因組序列轉變臨床指南，進一步最佳化治療結果。

基因組學市場人工智慧的促進因素：

  • 人工智慧技術在各個領域的日益普及預計將擴大基因組學領域人工智慧的全球市場。

精準醫學正在擴大基因組學領域的人工智慧市場。精準醫學考慮到一個人獨特的基因組成、外部條件和生活方式的決定，以製定快速採取行動的個人化治療計劃。人工智慧技術的進步可以處理大規模基因組資料來識別模式，根據能力和相似性將它們關聯起來，並幫助啟動個人化治療。

此外，人工智慧正在被納入某些領域（主要是癌症）的醫療保健和治療領域的精準醫療應用。人工智慧可用於分析基因組資料、癌症突變的基因組成，並識別有利於患者康復的最佳治療方法。它還可以識別出患有某些癌症的高風險族群，從而實現更早檢測和更有針對性的治療。隨著癌症患者數量的增加，基因組學領域的人工智慧市場可能會看到機會。

根據國際癌症控制聯盟（UICC）預測，到2050年，新增癌症患者將超過3500萬人。預計這一數字將比 2022 年報告的約 2,000 萬人增加 77%。低 HDI 國家的絕對增幅最大，為 142%，其次是中等 HDI 國家，為 99%。同時，到 2050 年，這些國家的癌症死亡人數預計將增加近一倍。

基因組學市場中人工智慧的地理格局：

  • 北美地區預計將佔據人工智慧工程市場的重要佔有率。

北美是基因組學人工智慧的重要市場，因為該地區擁有大量的基因組學公司、基因組學研究的大量資金籌措以及醫療保健系統的開發。此外，基於人工智慧的基因組學產品和應用的進步以及對個人化治療的需求不斷成長正在推動未來幾年的市場擴張。

此外，在美國和加拿大等北美國家，隨著政府和私人組織增加對基因組研究的投資，人工智慧在醫療保健領域的採用正在增加。此外，龐大的患者基礎也可能推動該地區的市場擴張。

為什麼要購買這份報告？

  • 洞察分析：深入洞察關鍵和新興地區的市場，重點關注客戶群、政府政策和社會經濟因素、消費者偏好、產業領域和其他子區隔。
  • 競爭格局：了解世界主要企業採取的策略策略，並了解透過正確的策略滲透市場的潛力。
  • 市場促進因素和未來趨勢：探索動態因素和關鍵市場趨勢以及它們將如何塑造未來市場開拓。
  • 可行的建議：利用洞察力做出策略決策，在動態環境中釋放新的業務流和收益。
  • 面向廣大受眾：對於新興企業、研究機構、顧問、中小型企業和大型企業有用且具有成本效益。

公司使用我們的報告的目的是什麼？

產業和市場考量、機會評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、法律規範與影響、新產品開拓、競爭影響

調查範圍

  • 過去的資料/預測，2022-2029
  • 成長機會、挑戰、供應鏈前景、法規結構、顧客行為、趨勢分析
  • 競爭對手的市場狀況、策略與市場佔有率分析
  • 包括國家在內的細分市場和地區的收益成長和預測評估
  • 公司簡介（策略、產品、財務資訊、主要發展等）

目錄

第1章簡介

  • 市場概況
  • 市場定義
  • 調查範圍
  • 市場區隔
  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關人員的主要利益

第2章調查方法

  • 研究設計
  • 調查過程

第3章執行摘要

  • 主要發現

第4章市場動態

  • 市場促進因素
  • 市場限制因素
  • 波特五力分析
  • 產業價值鏈分析
  • 分析師觀點

第5章 基因組學中的人工智慧市場：透過提供

  • 介紹
  • 軟體工具
  • 服務

第6章 基因組學中的人工智慧市場：按應用分類

  • 介紹
  • 精準醫療
  • 診斷/預後
  • 藥物發現/藥物開發
  • 農業和畜牧業
  • 其他

第7章 基因組學中的人工智慧市場：按最終用戶分類

  • 介紹
  • 製藥和生物技術公司
  • 學術/研究機構
  • 醫院/診斷中心
  • 其他

第8章 基因組學人工智慧市場：按地區

  • 介紹
  • 北美洲
    • 透過提供
    • 按用途
    • 按最終用戶
    • 按國家/地區
  • 南美洲
    • 透過提供
    • 按用途
    • 按最終用戶
    • 按國家/地區
  • 歐洲
    • 透過提供
    • 按用途
    • 按最終用戶
    • 按國家/地區
  • 中東/非洲
    • 透過提供
    • 按用途
    • 按最終用戶
    • 按國家/地區
  • 亞太地區
    • 透過提供
    • 按用途
    • 按最終用戶
    • 按國家/地區

第9章競爭環境及分析

  • 主要企業及策略分析
  • 市場佔有率分析
  • 合併、收購、協議和合作
  • 競爭對手儀表板

第10章 公司簡介

  • IBM
  • Sophia Genetics SA
  • QIAGEN NV
  • Fabric Genomics, Inc.
  • Congenica Ltd.
  • Illumina, Inc.
  • Freenome Holdings, Inc.
  • Data4cure, Inc.
  • Tempus Labs, Inc.
  • NVIDIA Corporation
簡介目錄
Product Code: KSI061614431

Artificial Intelligence (AI) in the Genomics Market is projected to witness a CAGR of 32.53% during the forecast period to reach a total market size of US$7,785.766 million by 2029, up from US$1,904.018 million in 2024.

The AI in the genomics market is growing rapidly with the rising demand for precision drugs and targeted therapies for specific health disorders. The market is anticipated to expand due to the burgeoning genomics research initiatives and the increasing demand for better data management and integration solutions. It is employed in all areas of drug discovery, disease diagnosis, and treatment planning to find new drug targets and improve therapeutic efficacy.

Moreover, it can analyze large genomic data datasets for disease diagnostics and identify early-onset disease signals by customizing the treatment planning per the patient's condition. AI could additionally optimize treatment results by transforming the clinical guidelines according to the genome sequence, with AI detecting a new way into the genomics market in the future.

AI IN GENOMICS MARKET DRIVERS:

  • Growing adoption of AI technology across different sectors is expected to increase the global market for AI in genomics.

Precision medicine is expanding the market for AI in genomics. Precision medicine considers an individual's unique genetic makeup, external conditions, and lifestyle decisions to create personalized treatment plans that take action rapidly. AI technological advancements can process large cohorts of genomic data to identify patterns and correlate them depending on capability or similarity, assisting in initiating personalized treatments.

Furthermore, AI has been incorporated into precision medicine applications in healthcare and treatment concerning some areas, mainly cancer. AI can be used to analyze genomic data, i.e., the genetic makeup of a mutation in cancer, and recognize the best therapies beneficial for the patient's recovery. It can also be harnessed to identify people who have an increased risk of developing certain cancers, facilitating earlier detection and more targeted treatment capabilities. The market for AI in genomics is potentially finding opportunities with growing cancer cases.

According to the Union for International Cancer Control (UICC), by 2050, an estimated over 35 million new cancer cases are projected to occur. This figure is a predicted increase of 77% from approximately 20 million reported in 2022. The most substantial absolute increases are for low HDI countries, with an increment of 142%, followed by medium-HDI countries, with a rise of 99%. At the same time, cancer deaths are expected to nearly double in these countries by 2050.

AI In Genomics Market Geographical Outlook:

  • The North American region is expected to hold a substantial artificial intelligence engineering market share.

North America is a significant market for AI in genomics due to numerous genomics firms, significant financing in genomics research, and a developed healthcare system. Additionally, the advancement of AI-based genomics products and applications, as well as the rising demand for personalized treatment, are propelling market expansion in the coming years.

Moreover, North American countries like the United States and Canada are increasing the employment of AI in healthcare, and government and private organizations are increasing investments in genomics studies. Further, the presence of a sizable patient base will also promote the advancement of the market in the region.

Reasons for buying this report:-

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, other sub- segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape up future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decision to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data & forecasts from 2022 to 2029
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, Customer Behaviour, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)

Market Segmentation:

The AI in Genomics Market is segmented and analyzed as below:

By Offering

  • Software tools
  • Services

By Application

  • Precision medicine
  • Diagnosis and prognosis
  • Drug discovery and development
  • Agriculture and animal breeding
  • Others

By End-User

  • Pharmaceutical and biotechnology companies
  • Academic and research institutes
  • Hospitals and diagnostic centers
  • Others

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • Israel
  • UAE
  • Others
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Vietnam
  • Indonesia
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key benefits for the stakeholders

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Process

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. AI IN GENOMICS MARKET BY OFFERING

  • 5.1. Introduction
  • 5.2. Software tools
  • 5.3. Services

6. AI IN GENOMICS MARKET BY APPLICATION

  • 6.1. Introduction
  • 6.2. Precision medicine
  • 6.3. Diagnosis and prognosis
  • 6.4. Drug discovery and development
  • 6.5. Agriculture and animal breeding
  • 6.6. Others

7. AI IN GENOMICS MARKET BY END-USER

  • 7.1. Introduction
  • 7.2. Pharmaceutical and biotechnology companies
  • 7.3. Academic and research institutes
  • 7.4. Hospitals and diagnostic centers
  • 7.5. Others

8. AI IN GENOMICS MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Offering
    • 8.2.2. By Application
    • 8.2.3. By End-User
    • 8.2.4. By Country
      • 8.2.4.1. USA
      • 8.2.4.2. Canada
      • 8.2.4.3. Mexico
  • 8.3. South America
    • 8.3.1. By Offering
    • 8.3.2. By Application
    • 8.3.3. By End-User
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
      • 8.3.4.2. Argentina
      • 8.3.4.3. Others
  • 8.4. Europe
    • 8.4.1. By Offering
    • 8.4.2. By Application
    • 8.4.3. By End-User
    • 8.4.4. By Country
      • 8.4.4.1. United Kingdom
      • 8.4.4.2. Germany
      • 8.4.4.3. France
      • 8.4.4.4. Spain
      • 8.4.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. By Offering
    • 8.5.2. By Application
    • 8.5.3. By End-User
    • 8.5.4. By Country
      • 8.5.4.1. Saudi Arabia
      • 8.5.4.2. Israel
      • 8.5.4.3. UAE
      • 8.5.4.4. Others
  • 8.6. Asia Pacific
    • 8.6.1. By Offering
    • 8.6.2. By Application
    • 8.6.3. By End-User
    • 8.6.4. By Country
      • 8.6.4.1. China
      • 8.6.4.2. Japan
      • 8.6.4.3. India
      • 8.6.4.4. South Korea
      • 8.6.4.5. Australia
      • 8.6.4.6. Vietnam
      • 8.6.4.7. Indonesia
      • 8.6.4.8. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. IBM
  • 10.2. Sophia Genetics SA
  • 10.3. QIAGEN N.V.
  • 10.4. Fabric Genomics, Inc.
  • 10.5. Congenica Ltd.
  • 10.6. Illumina, Inc.
  • 10.7. Freenome Holdings, Inc.
  • 10.8. Data4cure, Inc.
  • 10.9. Tempus Labs, Inc.
  • 10.10. NVIDIA Corporation